Captaru
  • Grants
  • Volunteers
  • Community
  • Pricing
  • About
    Who We AreOur PartnersJobs
  • Transparency
  • Blog
  • Contact
Captaru Logo

Starting from what we can do and think, our strength is bringing our own and third-party social projects to life.

proyectos@captaru.org
CAPTARU
  • ABOUT US
  • PROJECTS
  • Grant management
  • NGO platform
  • EU funding
  • TRANSPARENCY
  • CONTACT
FOLLOW US
  • Facebook
  • Twitter
  • LinkedIn
  • Youtube
Preferred source on Google
JOIN OUR NEWSLETTER AND NEVER MISS AN OPPORTUNITY
Legal NoticeDisclaimerCookie PolicyPrivacy StatementSubscription Terms

Fundación Plaza de Castilla, CIF G84070945, registered at Serrano Anguita 13, 28004 Madrid.

CAPTARU IS A PROJECT DEVELOPED WITH PASSION BY FUNDACIÓN PLAZA DE CASTILLA © 2026 ALL RIGHTS RESERVED

Back to list
Start a proposal with Captaru
🇺🇸GRANTS_GOVOPENGRANT241 days left

Enhancing Mechanistic Research on Precision Probiotic Therapies (R61/R33 Clinical Trial Optional)

🏛 GRANTS_GOV · 📍 US

Total budget

Not specified

OPENING

Oct 31, 2024

CLOSING

Jun 2, 2027

Category

Education / Health

Description

The purpose of this notice of funding opportunity (NOFO) is to support highly innovative mechanistic research to accelerate precision probiotic interventions using a milestone-driven, biphasic award mechanism, R61/R33 Phased Innovation Award. Specifically, this NOFO solicits applications that will characterize person-specific features affecting probiotic responses to identify subgroups of probiotic responders and to enhance probiotic clinical outcomes. The ultimate goal of this NOFO is to identify, understand, and develop strategies to address barriers in precision probiotic therapies to account for the heterogenicity in humans that causes inconsistent probiotic responses. The first phase, funded by the R61, will providing for up to 2 years to identify unique host biological patterns (e.g., native microbiome, immune system, gender, diet, age, genetic background, lifestyle, and health history) that are correlated with heterogeneity of probiotic clinical effects using observational or secondary data analysis studies. The second phase, funded under the R33, will support studies to assess the ability of the unique patterns determined in the R61 phase to detect the improvement of probiotic responsiveness in rigorously designed mechanistic studies in relevant animal models or in human subjects. The combined R61/R33 should not exceed 5 years. Transition from the R61 to the R33 phase of the award will be administratively reviewed and will be determined based on successful completion of Transition Milestones that need to be clearly specified in the R61 phase application. Support for a single phased award that does not need the R61 Exploratory phase is available in the companion (R33) NOFO, PAR-AT-24-XXX (TEMP-25413).

Official source

View official source ↗

Eligible beneficiaries

  • For profit organizations other than small businesses
  • Public housing authorities/Indian housing authorities
  • Special district governments
  • Others (see text field entitled "Additional Information on Eligibility" for clarification)
  • State governments
  • City or township governments
  • Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
  • Native American tribal organizations (other than Federally recognized tribal governments)
  • County governments
  • Public and State controlled institutions of higher education
  • Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
  • Independent school districts
  • Native American tribal governments (Federally recognized)
  • Private institutions of higher education
  • Small businesses

Related calls

  • Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)
  • Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
  • Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed)
  • NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Required)
  • NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Not Allowed)
  • Developing novel theory and methods for understanding the genetic architecture of complex human traits (R01 Clinical Trial Not Allowed)
See all open grants